Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 7,066 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urological Disease Clear all
Completed Phase 1Phase 2 Interventional Results available

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

NCT00126503
View directory record Official record
Conditions
Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions
Bevacizumab, Sorafenib Tosylate, Pharmacological Study, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
5
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Oct 27, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Results available

A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions

NCT01879683
View directory record Official record
Conditions
Chronic Interstitial Cystitis
Interventions
LiRIS® 400 mg
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Daytona Beach, Florida • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Oct 27, 2026, 1:33 PM EDT
Not yet recruiting Phase 1 Interventional

A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics

NCT07371429
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Gepotidacin, SOC
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 11 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Orange, California • Shreveport, Louisiana • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 1:33 PM EDT
Recruiting Not applicable Interventional

BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder

NCT04873037
View directory record Official record
Conditions
Overactive Bladder Syndrome, Overactive Bladder, Urinary Frequency, Urinary Urgency
Interventions
BTL Emsella Chair, Sham BTL Emsella Chair
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 27, 2026, 1:33 PM EDT
Terminated Not applicable Interventional

Randomized Fistula Study

NCT00808561
View directory record Official record
Conditions
Renal Failure
Interventions
Group 1: Alternative Fistula, Group 2: Forearm AV Graft
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 27, 2026, 1:33 PM EDT
Terminated Not applicable Interventional Results available

Sacral Nerve Stimulation in Improving Bladder Function After Acute Traumatic Spinal Cord Injury

NCT03083366
View directory record Official record
Conditions
Spinal Cord Injury, Acute, Neurogenic Bladder, Incontinence, Urinary Tract Infections
Interventions
PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Downey, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 27, 2026, 1:33 PM EDT
Completed Not applicable Interventional Results available

InterStim® Sacral Nerve Modulation Cycling Study

NCT01957137
View directory record Official record
Conditions
Urinary Urge Incontinence
Interventions
InterStim® (Device Programming)
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
St. Petersburg, Florida • Iowa City, Iowa • Woodbury, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 27, 2026, 1:33 PM EDT
Completed Not applicable Interventional Results available

Learning Alerts for Acute Kidney Injury

NCT02786277
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Alert
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
2,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 27, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

Dosing Study of Replagal in Patients With Fabry Disease

NCT00068107
View directory record Official record
Conditions
Fabry Disease
Interventions
Replagal
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 27, 2026, 1:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

EHR-integrated rUTI Texting Platform

NCT06035601
View directory record Official record
Conditions
Recurrent Urinary Tract Infection
Interventions
EHR-integrated texting platform (Urotrust), Usual care
Device · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 27, 2026, 1:33 PM EDT
Terminated Phase 2 Interventional Results available

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

NCT04430036
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
AGEN1884, AGEN2034, Cisplatin, Gemcitabine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 27, 2026, 1:33 PM EDT
Recruiting Phase 1 Interventional

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

NCT06778863
View directory record Official record
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Bladder Cancer
Interventions
CLSP-1025
Drug
Lead sponsor
Clasp Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 27, 2026, 1:33 PM EDT
Completed Not applicable Interventional Results available

Dietary Acid Load, Kidney Function and Disability in Elderly

NCT02691663
View directory record Official record
Conditions
Chronic Kidney Disease, Disability
Interventions
Oral bicarbonate supplementation, Placebo
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Oct 27, 2026, 1:33 PM EDT
Completed Not applicable Interventional

Dietary Protein Requirements in Hemodialysis Patients

NCT02194114
View directory record Official record
Conditions
Chronic Renal Failure, End-Stage Renal Disease
Interventions
Protein Diet
Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
25 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 27, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

NCT03430895
View directory record Official record
Conditions
Non-Transitional Cell Carcinoma of the Urothelial Tract, Small Cell of the Bladder, Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Metastatic Bladder Cancer
Interventions
durvalumab and tremelimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 27, 2026, 1:33 PM EDT
Not listed Early Phase 1 Interventional

Repetitive Transcranial Magnetic Stimulation in Women With Overactive Bladder With Urgency Incontinence

NCT05099419
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence
Interventions
Repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 27, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

NCT03617536
View directory record Official record
Conditions
Chronic Kidney Diseases, Pruritus
Interventions
CR845 0.25 mg Oral Tablet, CR845 0.5 mg Oral Tablet, CR845 1 mg Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
60
States / cities
Birmingham, Alabama • Florence, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 27, 2026, 1:33 PM EDT
Active, not recruiting Phase 1 Interventional

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

NCT06294236
View directory record Official record
Conditions
Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Interventions
SC291
Biological
Lead sponsor
Sana Biotechnology
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 27, 2026, 1:33 PM EDT
Active, not recruiting No phase listed Observational

Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study

NCT06350734
View directory record Official record
Conditions
Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 27, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.

NCT04699032
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Apraglutide
Drug
Lead sponsor
VectivBio AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 27, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis

NCT00677092
View directory record Official record
Conditions
Nephrogenic Systemic Fibrosis
Interventions
Imatinib mesylate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 27, 2026, 1:33 PM EDT
Completed Not applicable Interventional Results available

Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS)

NCT04492007
View directory record Official record
Conditions
Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions
Patient-Reported Outcomes-Informed Symptom Management System (PRISMS)
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 27, 2026, 1:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects

NCT03836599
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Verinurad, Allopurinol, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 27, 2026, 1:33 PM EDT
Completed Not applicable Interventional

Trial of Carbamylation in Renal Disease-Modulation With Amino Acid Therapy

NCT02472834
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis
Interventions
Amino acid supplementation NephrAmine®
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 27, 2026, 1:33 PM EDT